Nikhil Hebbar
University of Kentucky
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nikhil Hebbar.
Journal of Cellular Physiology | 2012
Nikhil Hebbar; Chi Wang; Vivek M. Rangnekar
Par‐4 is a pro‐apoptotic, tumor suppressor protein that induces apoptosis selectively in cancer cells. Endoplasmic reticulum‐stress and higher levels of protein kinase A in tumor cells confer the coveted feature of cancer selective response to extracellular and intracellular Par‐4, respectively. Recent studies have shown that systemic Par‐4 confers resistance to tumor growth in mice, and that tumor‐resistance is transferable by bone‐marrow transplantation. Moreover, recombinant Par‐4 inhibits the growth of tumors in mice. As systemic Par‐4 induces apoptosis via cell surface GRP78, strategies that promote GRP78 trafficking to the cell surface are expected sensitize cancer cells to circulating levels of Par‐4. This review illustrates the domains and mechanisms by which Par‐4 orchestrates the apoptotic process in both cell culture models and in physiological settings. J. Cell. Physiol. 227: 3715–3721, 2012.
Cancer Research | 2013
Ravshan Burikhanov; Shirley Qiu; Nidhi Shukla; Nikhil Hebbar; Subodh M. Lele; Craig Horbinski; Vivek M. Rangnekar
Tumor suppressor PAR-4 acts in part by modulating sensitivity to apoptosis, but the basis for its activity is not fully understood. In this study, we describe a novel mechanism of antiapoptosis by NF-κB, revealing that it can block PAR-4-mediated apoptosis by downregulating trafficking of the PAR-4 receptor GRP78 from the endoplasmic reticulum to the cell surface. Mechanistic investigations revealed that NF-κB mediated this antiapoptotic mechanism by upregulating expression of UACA, a proinflammatory protein in certain disease settings. In clinical specimens of cancer, a strong correlation existed between NF-κB activity and UACA expression, relative to normal tissues. UACA bound to intracellular PAR-4 in diverse cancer cells, where it prevented translocation of GRP78 from the endoplasmic reticulum to the cell surface. This pathway of antiapoptosis could be inhibited by suppressing levels of NF-κB or UACA expression, which enhanced endoplasmic reticulum stress and restored GRP78 trafficking to the cell surface, thereby sensitizing cancer cells to apoptosis by extracellular PAR-4 or GRP78 agonistic antibody. In summary, our results identify a novel intracellular pathway of apoptosis mediated by NF-κB through UACA elevation, which by attenuating endoplasmic reticulum stress and GRP78 translocation to the cell surface can blunt the sensitivity of cancer cells to apoptosis.
Cell Reports | 2014
Ravshan Burikhanov; Nikhil Hebbar; Shirley Qiu; Yanming Zhao; Gerard P. Zambetti; Vivek M. Rangnekar
The guardian of the genome, p53, is often mutated in cancer and may contribute to therapeutic resistance. Given that p53 is intact and functional in normal tissues, we harnessed its potential to inhibit the growth of p53-deficient cancer cells. Specific activation of p53 in normal fibroblasts selectively induced apoptosis in p53-deficient cancer cells. This paracrine effect was mediated by p53-dependent secretion of the tumor suppressor Par-4. Accordingly, the activation of p53 in normal mice, but not p53(-)/(-) or Par-4(-)/(-) mice, caused systemic elevation of Par-4, which induced apoptosis of p53-deficient tumor cells. Mechanistically, p53 induced Par-4 secretion by suppressing the expression of its binding partner, UACA, which sequesters Par-4. Thus, normal cells can be empowered by p53 activation to induce Par-4 secretion for the inhibition of therapy-resistant tumors.
Nature Chemical Biology | 2014
Ravshan Burikhanov; Vitaliy M. Sviripa; Nikhil Hebbar; Wen Zhang; W John Layton; Adel Hamza; Chang-Guo Zhan; David S. Watt; Chunming Liu; Vivek M. Rangnekar
The tumor suppressor protein Par-4, which is secreted by normal cells, selectively induces apoptosis in cancer cells. We identified a 3-arylquinoline derivative, designated Arylquin 1, as a potent Par-4 secretagogue in cell cultures and mice. Mechanistically, Arylquin 1 binds to vimentin, displaces Par-4 from vimentin for secretion and triggers the efficient paracrine apoptosis of diverse cancer cells. Thus, targeting vimentin with Par-4 secretagogues efficiently induces paracrine apoptosis of tumor cells.
Cancer Research | 2017
Nikhil Hebbar; Ravshan Burikhanov; Nidhi Shukla; Shirley Qiu; Yanming Zhao; Kojo S.J. Elenitoba-Johnson; Vivek M. Rangnekar
Primary tumors are often heterogeneous, composed of therapy-sensitive and emerging therapy-resistant cancer cells. Interestingly, treatment of therapy-sensitive tumors in heterogeneous tumor microenvironments results in apoptosis of therapy-resistant tumors. In this study, we identify a prostate apoptosis response-4 (Par-4) amino-terminal fragment (PAF) that is released by diverse therapy-sensitive cancer cells following therapy-induced caspase cleavage of the tumor suppressor Par-4 protein. PAF caused apoptosis in cancer cells resistant to therapy and inhibited tumor growth. A VASA segment of Par-4 mediated its binding and degradation by the ubiquitin ligase Fbxo45, resulting in loss of Par-4 proapoptotic function. Conversely, PAF, which contains this VASA segment, competitively bound to Fbxo45 and rescued Par-4-mediated induction of cancer cell-specific apoptosis. Collectively, our findings identify a molecular decoy naturally generated during apoptosis that inhibits a ubiquitin ligase to overcome therapy resistance in tumors. Cancer Res; 77(15); 4039-50. ©2017 AACR.
Cell Reports | 2017
Ravshan Burikhanov; Nikhil Hebbar; Sunil K. Noothi; Nidhi Shukla; James Sledziona; Nathália Araujo; Meghana Kudrimoti; Qing Jun Wang; David S. Watt; Danny R. Welch; Jodi K. Maranchie; Akihiro Harada; Vivek M. Rangnekar
SUMMARY The induction of tumor suppressor proteins capable of cancer cell apoptosis represents an attractive option for the re-purposing of existing drugs. We report that the anti-malarial drug, chloroquine (CQ), is a robust inducer of Par-4 secretion from normal cells in mice and cancer patients in a clinical trial. CQ-inducible Par-4 secretion triggers paracrine apoptosis of cancer cells and also inhibits metastatic tumor growth. CQ induces Par-4 secretion via the classical secretory pathway that requires the activation of p53. Mechanistically, p53 directly induces Rab8b, a GTPase essential for vesicle transport of Par-4 to the plasma membrane prior to secretion. Our findings indicate that CQ induces p53- and Rab8b-dependent Par-4 secretion from normal cells for Par-4-dependent inhibition of metastatic tumor growth.
Advances in Experimental Medicine and Biology | 2014
Nikhil Hebbar; Vivek M. Rangnekar
Tumor suppressor genes play an important role in preventing neoplastic transformation and maintaining normal tissue homeostasis. Par-4 is one such tumor suppressor which is unique in its ability to selectively induce apoptosis in cancer cells while leaving the normal cells unaffected. The cancer cell specific activity of Par-4 is elicited through intracellular as well as extracellular mechanisms. Intracellularly Par-4 acts through the inhibition of pro-survival pathways and activation of Fas mediated apoptosis whereas extracellular (secreted Par-4) acts by binding to cell surface GRP78 leading to activation of the extrinsic apoptotic pathway. Many studies have highlighted the importance of Par-4 not only in preventing cancer development/recurrence but also as a promising anticancer therapeutic agent.
Cancer Cell | 2013
Nikhil Hebbar; Vivek M. Rangnekar
Women suffering from breast cancer often succumb to incurable recurrent disease resulting from therapy-resistant cancer cells. In this issue of Cancer Cell, Alvarez and colleagues identify downregulation of the tumor suppressor Par-4 as the key determinant in apoptosis evasion, which leads to tumor recurrence in breast cancer.
EBioMedicine | 2018
Nathália Araujo; Nikhil Hebbar; Vivek M. Rangnekar
Glucose-Regulated Protein 78 (GRP Immunoglobulin Protein), is a membe 78), also known as BiP (Binding r of the Hsp70 family of chaperone proteins that is essential for embryonic development. GRP78 is highly conserved across species, and is localized primarily in the endoplasmic reticulum, where it regulates protein folding and activates the unfolded protein response pathway (UPR) during stress conditions [6]. Under normal conditions, GRP78 binds to and inactivates the ER stress sensors ATF-6, PERK and IRE1. ER stress drives the accumulation of unfolded proteins to titrate GRP78 away from the stress sensors toward plasma membrane localization. GRP78 is highly expressed on the cell surface of a variety of cancer types owing to their inherently elevated ER stress levels, andweakly expressed on normal cells [8]. Global profiling of cell surface GRP78 is highly correlated with pathological states making it a relevant target for therapy. Several natural ligands can elicit a diverse signaling response upon binding to cell surface GRP78. On tumor cells, GRP78 can bind to α2macroglobulin and Cripto, leading to cell survival and proliferation, or to Kringle 5 and Par-4, which drives apoptosis [3]. On endothelial
Cancer Research | 2015
Ravshan Burikhanov; Nikhil Hebbar; Shirley Qiu; Yanming Zhao; Gerard P. Zambetti; Vivek M. Rangnekar
The guardian of the genome, p53, is mutated or functionally inactivated in a majority of human cancers. However, p53 in normal cells is intact and functional. In the present study, we tested the potential of wild-type p53 in normal tissues to inhibit the growth of p53-deficient cancer cells. Co-culture experiments of normal fibroblasts with cancer cells revealed that specific activation of p53 in normal fibroblasts selectively induced apoptosis in p53-deficient cancer cells. Moreover, this paracrine apoptotic effect of p53 was attributed to an enhanced secretion of the tumor suppressor Par-4 in response to p53 activation. Mechanistically, p53 represses the expression of UACA, a binding partner of Par-4, by directly binding to its signature motif in the UACA gene. Down-regulation of UACA expression liberates Par-4 from sequestration, and thus induces its secretion. Consistent with our cell culture studies, animal experiments also show that activation of p53 results in an elevation of systemic Par-4 levels in p53 +/+ mice, which can induce apoptosis in p53-deficient cancer cells in ex vivo experiments. By contrast, p53 activators failed to induce this paracrine effect in p53 -/- or Par-4 -/- mice. Thus, by activating wild-type p53, normal cells can be empowered to inhibit tumor growth, progression, and metastasis. Citation Format: Tripti Shrestha-Bhattarai, Ravshan Burikhanov, Nikhil Hebbar, Shirley Qiu, Yanming Zhao, Gerard P. Zambetti, Vivek M. Rangnekar. Paracrine apoptotic effect of the tumor suppressor p53 is mediated by secreted Par-4. [abstract]. In: Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr A52. doi:10.1158/1538-7445.CHTME14-A52